NLS Pharmaceutics AG (NLSP) Company Profile - Business Overview, Management Team & Corporate Information - Stocknear

NLS Pharmaceutics AG

NASDAQ: NLSP · Real-Time Price · USD
2.19
0.13 (6.31%)
At close: Sep 26, 2025, 3:59 PM
2.22
1.37%
After-hours: Sep 26, 2025, 07:48 PM EDT

Company Description

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders.

The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).

Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD.

The company was incorporated in 2015 and is based in Zurich, Switzerland.

NLS Pharmaceutics AG
NLS Pharmaceutics AG logo
Country CH
IPO Date Jan 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Alexander Zwyer

Contact Details

Address:
The Circle 6
Zurich,
CH
Website https://nlspharma.com

Stock Details

Ticker Symbol NLSP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001783036
CUSIP Number H57830103
ISIN Number CH0523961370
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Alexander Zwyer M.B.A. Co-Founder, Chief Executive Officer & Director
Dr. Eric Konofal M.D., Ph.D. Co-Founder & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Sep 25, 2025 F-1 Filing
Sep 19, 2025 6-K Filing
Sep 10, 2025 424B3 Filing
Sep 10, 2025 6-K Filing
Sep 04, 2025 425 Filing
Sep 04, 2025 6-K Filing
Sep 03, 2025 F-4/A [Amend] Filing
Aug 29, 2025 425 Filing
Aug 29, 2025 6-K Filing
Aug 25, 2025 6-K Filing